Cargando…
Revaprazan, a novel acid pump antagonist, exerts anti-inflammatory action against Helicobacter pylori-induced COX-2 expression by inactivating Akt signaling
Chronic gastric inflammation developing after Helicobacter pylori (H. pylori) infection is responsible for either dyspeptic symptom relevant to gastritis/peptic ulcer or gastric tumorigenesis, in which acid suppressants, especially proton pump inhibitors (PPIs), play role in relieving dyspepsia as w...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
the Society for Free Radical Research Japan
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3432830/ https://www.ncbi.nlm.nih.gov/pubmed/22962522 http://dx.doi.org/10.3164/jcbn.11-94 |
_version_ | 1782242252207161344 |
---|---|
author | Lee, Jeong-Sang Cho, Ji-Yoon Song, Heup Kim, Eun-Hee Hahm, Ki-Baik |
author_facet | Lee, Jeong-Sang Cho, Ji-Yoon Song, Heup Kim, Eun-Hee Hahm, Ki-Baik |
author_sort | Lee, Jeong-Sang |
collection | PubMed |
description | Chronic gastric inflammation developing after Helicobacter pylori (H. pylori) infection is responsible for either dyspeptic symptom relevant to gastritis/peptic ulcer or gastric tumorigenesis, in which acid suppressants, especially proton pump inhibitors (PPIs), play role in relieving dyspepsia as well as the eradication regimen. Among several mediators engaged in propagating gastric inflammation after H. pylori infection, cyclooxygenase-2 (COX-2) might be the principal one, and several prescriptions have been made for decreasing the COX-2 levels. Multiple line of evidence are available for anti-inflammatory action of PPIs beyond acid suppression, but revaprazan, a novel acid pump antagonist launched in clinic, has also been suggested to exert significant anti-inflammatory actions as much as PPI. In the current study, we hypothesized that revaprazan could regulate H. pylori-driven COX-2 expression as one of its anti-inflammatory pharmacological actions. The changes of gastric COX-2 expression as well as responsible transcription factors were measured after H. pylori infection in the presence or absence of revaprazan. Infection of AGS cells with H. pylori induced significant up-regulation of COX-2 in time- and concentration-dependent manners, which was mediated by Akt phosphorylation. Revaprazan treatment significantly inhibited IkappaB-alpha degradation as well as Akt inactivation, resulting in attenuation of H. pylori-induced COX-2 expression. Additional rescuing action of revaprazan against H. pylori-induced cytotoxicity was noted. In conclusion, revaprazan imposed significant anti-inflammatory actions on H. pylori infection beyond acid suppression. |
format | Online Article Text |
id | pubmed-3432830 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | the Society for Free Radical Research Japan |
record_format | MEDLINE/PubMed |
spelling | pubmed-34328302012-09-07 Revaprazan, a novel acid pump antagonist, exerts anti-inflammatory action against Helicobacter pylori-induced COX-2 expression by inactivating Akt signaling Lee, Jeong-Sang Cho, Ji-Yoon Song, Heup Kim, Eun-Hee Hahm, Ki-Baik J Clin Biochem Nutr Original Article Chronic gastric inflammation developing after Helicobacter pylori (H. pylori) infection is responsible for either dyspeptic symptom relevant to gastritis/peptic ulcer or gastric tumorigenesis, in which acid suppressants, especially proton pump inhibitors (PPIs), play role in relieving dyspepsia as well as the eradication regimen. Among several mediators engaged in propagating gastric inflammation after H. pylori infection, cyclooxygenase-2 (COX-2) might be the principal one, and several prescriptions have been made for decreasing the COX-2 levels. Multiple line of evidence are available for anti-inflammatory action of PPIs beyond acid suppression, but revaprazan, a novel acid pump antagonist launched in clinic, has also been suggested to exert significant anti-inflammatory actions as much as PPI. In the current study, we hypothesized that revaprazan could regulate H. pylori-driven COX-2 expression as one of its anti-inflammatory pharmacological actions. The changes of gastric COX-2 expression as well as responsible transcription factors were measured after H. pylori infection in the presence or absence of revaprazan. Infection of AGS cells with H. pylori induced significant up-regulation of COX-2 in time- and concentration-dependent manners, which was mediated by Akt phosphorylation. Revaprazan treatment significantly inhibited IkappaB-alpha degradation as well as Akt inactivation, resulting in attenuation of H. pylori-induced COX-2 expression. Additional rescuing action of revaprazan against H. pylori-induced cytotoxicity was noted. In conclusion, revaprazan imposed significant anti-inflammatory actions on H. pylori infection beyond acid suppression. the Society for Free Radical Research Japan 2012-09 2012-07-20 /pmc/articles/PMC3432830/ /pubmed/22962522 http://dx.doi.org/10.3164/jcbn.11-94 Text en Copyright © 2012 JCBN This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Article Lee, Jeong-Sang Cho, Ji-Yoon Song, Heup Kim, Eun-Hee Hahm, Ki-Baik Revaprazan, a novel acid pump antagonist, exerts anti-inflammatory action against Helicobacter pylori-induced COX-2 expression by inactivating Akt signaling |
title | Revaprazan, a novel acid pump antagonist, exerts anti-inflammatory action against Helicobacter pylori-induced COX-2 expression by inactivating Akt signaling |
title_full | Revaprazan, a novel acid pump antagonist, exerts anti-inflammatory action against Helicobacter pylori-induced COX-2 expression by inactivating Akt signaling |
title_fullStr | Revaprazan, a novel acid pump antagonist, exerts anti-inflammatory action against Helicobacter pylori-induced COX-2 expression by inactivating Akt signaling |
title_full_unstemmed | Revaprazan, a novel acid pump antagonist, exerts anti-inflammatory action against Helicobacter pylori-induced COX-2 expression by inactivating Akt signaling |
title_short | Revaprazan, a novel acid pump antagonist, exerts anti-inflammatory action against Helicobacter pylori-induced COX-2 expression by inactivating Akt signaling |
title_sort | revaprazan, a novel acid pump antagonist, exerts anti-inflammatory action against helicobacter pylori-induced cox-2 expression by inactivating akt signaling |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3432830/ https://www.ncbi.nlm.nih.gov/pubmed/22962522 http://dx.doi.org/10.3164/jcbn.11-94 |
work_keys_str_mv | AT leejeongsang revaprazananovelacidpumpantagonistexertsantiinflammatoryactionagainsthelicobacterpyloriinducedcox2expressionbyinactivatingaktsignaling AT chojiyoon revaprazananovelacidpumpantagonistexertsantiinflammatoryactionagainsthelicobacterpyloriinducedcox2expressionbyinactivatingaktsignaling AT songheup revaprazananovelacidpumpantagonistexertsantiinflammatoryactionagainsthelicobacterpyloriinducedcox2expressionbyinactivatingaktsignaling AT kimeunhee revaprazananovelacidpumpantagonistexertsantiinflammatoryactionagainsthelicobacterpyloriinducedcox2expressionbyinactivatingaktsignaling AT hahmkibaik revaprazananovelacidpumpantagonistexertsantiinflammatoryactionagainsthelicobacterpyloriinducedcox2expressionbyinactivatingaktsignaling |